August 4, 2026

Gabapentin (Neurontin)

MDLinx published 6/24/2026 article by Davi Sherman suggesting that the non-opioid, non-benzodiazepine, non-cannibis product may have more side effects than clinically appreciated during the past decades of prescribing. Like opioids, it has been suggested that gabapentin (Neurontin) may suppress breathing during sleep even though opioids have long been contra-indicated prior to sleep and gabapentin has been prescribed to facilitate sleep. Studies conclusively proving causality of gabapentin to cause ventilatory suppression leading to cellular respiratory failure will need to include sleep monitoring machines in patients NOT co-consuming truly proven ventilatory suppressants (alcohol, opioids, benzodiazepines, barbiturates).

Concomitant with all sleep aids is an increased risk for falls with consequent fractures, brain injury, spinal cord injury,… Like benzodiazepines and cannabis, it has been suggested that gabapentin may increase risks for dementia. Again, studies truly proving causality are lacking. Nonetheless, now that a suggestion of potential harm exists, patients will need to choose volitionally to accept risks via informed consent just as they accept risks for quadriplegia and paraplegia from epidural steroid injections via honest informed consent. Patients unwilling to accept full accountability of risks will need to taper from gabapentin. Clinicians will continue to monitor patients for increased falls, dementia,… and all possible side effects as with all prescribed medications monitored by prescribers.

MDLinx concluded their article by quoting Sean Mackey, M.D. who stated: "The current dementia data should prompt clinical vigilance, not alarm. History teaches us that many early safety signals from administrative database bases fade with better-controlled studies."

(https://www.mdlinx.com/article/new-gabapentin-lawsuits-raise-a-question-for-physicians-is-your-documentation-enough/456W2H2vWXCKD7amWAuCS4, accessed 6/29/2026)

Patients should be aware that scrutiny of the gabapentin molecule reveals that it is extremely closely approximated to the molecular structure of pregabalin (Lyrica),(August 2009 Cleveland Clinic Journal of Medicine (76(8):481-2.)(Pregabalin: new drug. Very similar to gabapentin. Prescrire Int. 2005 Dec;14(80):203-6.)(Duvall, N.M., et al. "A Randomized Trial Evaluating Pregabalin Vs Gabapentin on Reducing Opioid Usage in Patients With Acute Trauma Injuries". Journal of Opioid Management, 2026 June;22(3), 241-9.) produced by the same manufacturer. Suggestions of suppression of breathing during sleep, dementia,…